Market Overview

UPDATE: JP Morgan Raises PT to $29 on Pfizer Following PD-991 Phase II Data

Related PFE
Will The New Pfizer Be A Winner? SunTrust Analyst Thinks So, Upgrades Stock
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Ad Comm approaches for Fabre-Kramer's MDD med (Seeking Alpha)

JP Morgan reiterated Pfizer (NYSE: PFE) at Overweight and increased its price target from $28 to $29.

JP Morgan commented, "Following last week's phase II data for PD-991 in breast cancer and further feedback from physicians, we believe the product represents the most promising of Pfizer's next-generation pipeline assets, and we are incorporating it into our model. We see PD-991 as a multi-billion product opportunity, addressing a large segment of the breast cancer market (first-line advanced/metastatic HER2-/ER+) with few treatment options. More broadly, we believe PFE shares remain positioned to outperform as the company continues with its business unit divestiture process, returns significant capital to shareholders, and enters an attractive new product launch cycle."

Pfizer closed at $25.51 on Wednesday.

Latest Ratings for PFE

Nov 2015SunTrust Robinson HumphreyUpgradesReduceNeutral
Nov 2015Argus ResearchMaintainsBuy
Oct 2015Cowen & CompanyUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters